<DOC>
	<DOCNO>NCT00842894</DOCNO>
	<brief_summary>This study conduct Europe . The aim observational study investigate incidence serious adverse drug reaction use NovoMix速 30 ( biphasic insulin aspart 30 ) Levemir速 ( insulin detemir ) treatment type 2 diabetes mellitus normal clinical practice condition Macedonia .</brief_summary>
	<brief_title>Safety NovoMix速 30 Levemir速 Treatment Type 2 Diabetics Macedonia</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>After physician decision make use biphasic insulin aspart 30 insulin detemir therapy , subject Type 2 diabetes eligible study , include newlydiagnosed subject never receive insulin insulin analogue before.Particular attention pay drug interaction list within product label Subjects unlikely comply protocol , e.g. , uncooperative attitude , inability return final visit Subjects currently treat biphasic insulin aspart 30 insulin detemir Subjects previously enrol study Subjects hypersensitivity biphasic insulin aspart 30 insulin detemir excipients Women pregnant , breast feeding intention become pregnant within next 6 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>